Feature | October 12, 2012

First Patient Enrolled in REPRISE II TAVR Trial to Evaluate Lotus Valve

REPRISE II study results expected to support CE mark and other regulatory filings

October 12, 2012 — Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus valve system in up to 120 patients with severe aortic valve disease. This international multicenter study includes 15 sites in Australia, France, Germany and the United Kingdom.  The Lotus valve system is the first transcatheter aortic valve replacement (TAVR) device of its kind that is designed to minimize aortic regurgitation (leaking). The device is both fully repositionable and retrievable prior to release, offering predictable and precise placement. The results of the REPRISE II trial are expected to be used to support CE mark and other international regulatory approvals.

"We were encouraged by the promising results of the REPRISE I clinical trial completed earlier this year, and we are therefore very confident about evaluating the safety and performance of the Lotus Valve in a larger patient cohort," said Ian Meredith, professor and director of Monash Heart at Monash Medical Center in Melbourne, Australia, and the principal investigator of the REPRISE II trial.  "The Lotus Valve has a number of important features which address some of the limitations observed with the first generation devices. The ease of use, predictable and precise positioning, and ability to fully reposition and retrieve the Lotus Valve offer the operator considerable reassurance and control. These features, along with the minimized risk of paravalvular leakage, may lead to improved clinical outcomes."

The Lotus valve system is a differentiated second-generation TAVR technology, which consists of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system used for guidance and percutaneous placement of the valve. The low-profile delivery system and introducer sheath are designed to enable predictable and precise placement, as well as bidirectional atraumatic repositioning and retrieval at any time prior to release of the aortic valve implant. The device also employs a Adaptive Seal feature designed to minimize the incidence of paravalvular regurgitation, which has proven to be a predictor of mortality.

Current study enrollment requires that patients have severe calcific aortic stenosis, are aged 70 years or older, and are considered to be at high surgical risk, defined as an STS (Society of Thoracic Surgeons) mortality score greater than 8 or by the consensus opinion of the heart team. The REPRISE II study is designed to study two valve sizes, 23 mm and 27 mm, and have a five-year follow-up.  Beyond that, it will assess for other endpoints recommended by the Valve Academic Research Consortium (VARC) and regulatory agencies. Study enrollment is expected to be completed in the first half of 2013.

"There is a high need for continued evolution of device technology to treat people with severe aortic valve disease," said Keith D. Dawkins, M.D., global chief medical officer for Boston Scientific. "We are looking forward to advancing the Boston Scientific valve program with REPRISE II, as we believe the Lotus valve system is a unique technology that will offer interventional cardiologists greater precision and control in deployment which, in effect, may simplify the implantation procedure and lead to improved patient outcomes."

The Lotus Valve System is an investigational device, limited by applicable law to investigational use and not available for sale. The device was developed by Sadra Medical, which Boston Scientific acquired in 2011.

For more information: www.sadramedical.com

Related Content

If MitraClip Fails 95 Percent of Patients Will Need Full Surgical Valve Replacement according to a late-breaking study at the AATS 2021 meeting. #AATS2021

If MitraClip fails and a surgical repair is required, a late-breaking study presented at the 2021 AATS meeting showed 95 percent of patients will require a full surgical valve replacement.

News | Heart Valve Technology | May 04, 2021
May 4, 2021 – A new study, presented at the 2021 American Association f...
University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. This can be implanted in pediatric patients with congenital heart diseas. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

University of Minnesota researchers used a hybrid of tissue engineering and regenerative medicine to create heart valves that can grow with the recipient. When implanted in lambs, researchers showed that the tri-tube valves worked better than current animal-derived valves with almost none of the calcification or blood clotting that the other valves showed. Photo from Syedain, et al., Tranquillo Lab, University of Minnesota

News | Heart Valve Technology | March 18, 2021
March 18, 2020 — A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the Coll
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session.
News | Heart Valve Technology | February 04, 2021
February 4, 2021 — Transcatheter aortic valve replacement (TAVR) has historically only been used with caution in the
Foldax Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) so the company to initiate a U.S. clinical study of its Tria biopolymer mitral surgical heart valve.
News | Heart Valve Technology | December 14, 2020
December 14, 2020 - Foldax Inc. today announced that the U.S.

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. 

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart